Minerva Neurosciences Inc (NAS:NERV)
$ 2.46 -0.02 (-0.81%) Market Cap: 17.21 Mil Enterprise Value: -17.48 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 37/100

Minerva Neurosciences Inc at JMP Securities Life Sciences Virtual Conference Transcript

Jun 16, 2021 / 02:00PM GMT
Release Date Price: $22.4
Jason Butler
JMP Group LLC - Analyst

Great. Good morning and welcome to the JMP Securities' life sciences conference. I am Jason Butler, Senior Biotechnology Analyst. Welcome, everybody. Really excited to kick things off this year with Minerva Neurosciences, where we are joined this morning by Remy Luthringer, the Company's CEO. Remy, great to see you; great to have you here.

Minerva is focused on the development of novel therapies for unmet needs in neuroscience, and specifically, their lead candidate, roluperidone, has completed a Phase III trial in patients with negative symptoms of schizophrenia. The Company is working towards FDA interactions towards an NDA submission.

And so we again welcome Remy. We'd love to just have a -- you give a quick intro and maybe just give us a little bit of the background of roluperidone and how you see the asset fitting into the unmet need. Thank you.

Remy Luthringer
Minerva Neurosciences, Inc. - Executive Chairman & CEO

Thank you so much, Jason. Yes, and really thank you for having us and having me,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot